Table 2 Genotype frequencies of APE1 polymorphisms among OS patients and normal control.

From: rs1760944 Polymorphism in the APE1 Region is Associated with Risk and Prognosis of Osteosarcoma in the Chinese Han Population

 

Cohorts

Genotype

OS Cases

Controls

HWE

OR (95%CI)

P

rs1130409

Cohort 1

TT

64 (37.2)

90 (35.1)

0.32

Reference

 
  

TG

79 (45.9)

117 (45.7)

 

0.95 (0.62–1.46)

0.82

  

GG

29 (16.9)

49 (19.2)

 

0.83 (0.48–1.46)

0.57

  

TG + GG

108 (62.8)

166 (64.9)

 

0.91 (0.61–1.37)

0.68

  

T

207 (60.2)

297 (58.0)

 

Reference

 
  

G

137 (39.8)

215 (42.0)

 

0.94 (0.69–1.21)

0.57

 

Cohort 2

TT

70 (34.0)

118 (32.8)

0.45

Reference

 
  

TG

99 (48.1)

170 (47.2)

 

0.98 (0.67–1.44)

0.51

  

GG

37 (17.9)

72 (20.0)

 

0.87 (0.53–1.42)

0.62

  

TG + GG

136 (66.0)

242 (67.2)

 

0.95 (0.66–1.36)

0.78

  

T

239 (58.0)

406 (56.4)

 

Reference

 
  

G

173 (42.0)

314 (43.6)

 

0.94 (0.73–1.20)

0.62

 

Combined

TT

134 (34.4)

208 (33.8)

 

Reference

 
  

TG

178 (47.1)

287 (46.6)

 

0.96 (0.72–1.28)

0.83

  

GG

66 (17.5)

121 (19.6)

 

0.85 (0.59–1.23)

0.40

  

TG + GG

244 (64.6)

408 (66.2)

 

0.93 (0.71–1.22)

0.63

  

T

446 (59.0)

703 (57.1)

 

Reference

 
  

G

310 (41.0)

529 (42.9)

 

0.92 (0.77–1.11)

0.40

rs1760944

Cohort 1

TT

80 (46.5)

86 (33.6)

0.58

Reference

 
  

TG

70 (40.7)

121 (47.3)

 

0.62 (0.41–0.95)

0.032

  

GG

22 (12.8)

49 (19.1)

 

0.48 (0.27–0.87)

0.015

  

TG + GG

92 (53.5)

170 (76.4)

 

0.58 (0.39–0.87)

0.009

  

T

230 (66.9)

293 (57.2)

 

Reference

 
  

G

114 (33.1)

219 (42.8)

 

0.66 (0.50–0.88)

0.005

 

Cohort 2

TT

83 (40.3)

108 (30.0)

0.97

Reference

 
  

TG

93 (45.1)

178 (49.4)

 

0.68 (0.47–0.99)

0.04

  

GG

30 (14.6)

74 (20.6)

 

0.53 (0.32–0.88)

0.017

  

TG + GG

123 (59.7)

252 (70.0)

 

0.64 (0.44–0.91)

0.016

  

T

259 (62.8)

394 (54.7)

 

Reference

 
  

G

153 (37.2)

326 (45.3)

 

0.71 (0.56–0.92)

0.009

 

Combined

TT

163 (0.43)

194 (0.31)

 

Reference

 
  

TG

163 (0.43)

299 (0.49)

 

0.65 (0.49–0.86)

0.003

  

GG

52 (0.16)

123 (0.20)

 

0.50 (0.34–0.74)

<0.01

  

TG + GG

215 (0.59)

422 (0.69)

 

0.61 (0.47–0.79)

<0.01

  

T

489 (0.65)

687 (0.56)

 

Reference

 
  

G

267 (0.35)

545 (0.44)

 

0.69 (0.57–0.83)

<0.01

rs2275008

Cohort 1

TT

125 (0.73)

200 (0.78)

0.187

Reference

 
  

TC

43 (0.25)

50 (0.20)

 

1.38 (0.86–2.19)

0.18

  

CC

4 (0.02)

6 (0.02)

 

1.07 (0.30–3.86)

0.58

  

TC + CC

47 (0.27)

56 (0.22)

 

1.34 (0.86–2.10)

0.21

  

T

293 (0.85)

450 (0.88)

 

Reference

 
  

C

51 (0.15)

62 (0.12)

 

1.26 (0.85–1.88)

0.26

 

Cohort 2

TT

151 (0.73)

273 (0.76)

 

Reference

 
  

TC

51 (0.25)

78 (0.21)

 

1.18 (0.79–1.77)

0.47

  

CC

4 (0.02)

9 (0.03)

 

0.80 (0.24–2.65)

0.49

  

TC + CC

55 (0.27)

87 (0.24)

 

1.14 (0.77–1.69)

0.55

  

T

353 (0.86)

624 (0.87)

 

Reference

 
  

C

59 (0.14)

96 (0.13)

 

1.08 (0.77–1.54)

0.65

 

Combined

TT

276 (0.73)

473 (0.77)

0.08

Reference

 
  

TC

94 (0.25)

128 (0.21)

 

1.26 (0.93–1.71)

0.16

  

CC

8 (0.02)

15 (0.02)

 

0.91 (0.38–2.18)

0.51

  

TC + CC

102 (0.27)

143 (0.23)

 

1.22 (0.91–1.64)

0.20

  

T

646 (0.85)

1074 (0.87)

 

Reference

 
  

C

110 (0.15)

158 (0.13)

 

1.16 (0.89–1.50)

0.28

rs17111750

Cohort 1

CC

105 (0.61)

156 (0.61)

0.121

Reference

 
  

CT

49 (0.28)

82 (0.32)

 

0.89 (0.58–1.37)

0.66

  

TT

18 (0.11)

18 (0.07)

 

1.49 (0.74–2.99)

0.28

  

CT + TT

67 (0.39)

100 (0.39)

 

0.99 (0.67–1.48)

0.53

  

C

259 (0.75)

394 (0.77)

 

Reference

 
  

T

85 (0.25)

118 (0.23)

 

1.10 (0.80–1.51)

0.62

 

Cohort 2

CC

125 (0.61)

183 (0.60)

0.08

Reference

 
  

CT

62 (0.30)

100 (0.32)

 

0.91 (0.62–1.34)

0.69

  

TT

19 (0.09)

23 (0.08)

 

1.21 (0.63–2.31)

0.62

  

CT + TT

81 (0.39)

123 (0.40)

 

0.96 (0.67–1.38)

0.85

  

C

312 (0.76)

466 (0.76)

 

Reference

 
  

T

100 (0.24)

146 (0.24)

 

1.02 (0.76–1.37)

0.88

 

Combined

CC

230 (0.61)

339 (0.60)

 

Reference

 
  

CT

111 (0.29)

182 (0.32)

 

0.90 (0.67–1.20)

0.51

  

TT

37 (0.10)

41 (0.07)

 

1.33 (0.83–2.14)

0.27

  

CT + TT

148 (0.39)

223 (0.40)

 

0.98 (0.75–1.28)

0.89

  

C

571 (0.76)

860 (0.77)

 

Reference

 
  

T

185 (0.24)

264 (0.23)

 

1.06 (0.85–1.31)

0.66

rs1760941

Cohort 1

CC

96 (0.56)

131 (0.51)

0.184

Reference

 
  

CA

63 (0.37)

98 (0.38)

 

0.88 (0.58–1.32)

0.60

  

AA

13 (0.07)

27 (0.11)

 

0.66 (0.32–1.34)

0.30

  

CA + AA

76 (0.44)

125 (0.49)

 

0.83 (0.56–1.22)

0.38

  

C

255 (0.74)

360 (0.70)

 

Reference

 
  

A

89 (0.26)

152 (0.30)

 

0.83 (0.61–1.12)

0.25

 

Cohort 2

CC

117 (0.57)

194 (0.54)

0.102

Reference

 
  

CA

71 (0.34)

132 (0.37)

 

0.89 (0.62–1.29)

0.58

  

AA

18 (0.09)

34 (0.09)

 

0.88 (0.47–1.63)

0.76

  

CA + AA

89 (0.43)

166 (0.46)

 

0.89 (0.63–1.26)

0.54

  

C

305 (0.74)

520 (0.72)

 

Reference

 
  

A

107 (0.26)

200 (0.28)

 

0.91 (0.69–1.20)

0.53

 

Combined

CC

213 (0.56)

325 (0.53)

 

Reference

 
  

CA

134 (0.35)

230 (0.37)

 

0.89 (0.68–1.17)

0.40

  

AA

31 (0.09)

61 (0.10)

 

0.78 (0.49–1.24)

0.30

  

CA + AA

165 (0.44)

291 (0.47)

 

0.87 (0.67–1.20)

0.29

  

C

560 (0.74)

880 (0.71)

 

Reference

 
  

A

196 (0.26)

352 (0.29)

 

0.87 (0.71–1.07)

0.22

Back to article page